Overview
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
Status:
Completed
Completed
Trial end date:
2010-01-01
2010-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trialPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Avexa
Criteria
Inclusion Criteria:- Completed AVX-201 protocol, Plasma HIV RNA <5000 copies/ml, CD4 cells >50
Exclusion Criteria:
- Pregnant or breastfeeding females, withdrawal from AVX-201